Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the Infusion of Donor Plasma in COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SARS CoV 2 infection, confirmed by PCR or technique of similar specificity.~* Symptom onset, or positive PCR (whichever comes first) within 7 days (168 hours) prior to planned plasma infusion.~* 65 years of age or older.~* All patients, or the guardian appointed by the judge, in the case of recognized judicial incapacity, must sign the informed consent document.~Exclusion Criteria:~* Less than 65 years of age~* Symptom onset, or positive PCR (whichever comes first), more than 7 days (168 hours) prior to planned plasma infusion.~* Severe dementia, or other significant comorbidity, that generates a serious deterioration of the baseline functional status, with a life expectancy of less than 6 months.~* Participation in another clinical trial or study.~* History of allergy to amotosalen or psoralens

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Treatment in the intervention group:~Infusion of 300 cc of convalescent donor plasma from COVID 19, administered within more than 168 hours from the onset of symptoms Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment.
- Control (Type: ACTIVE_COMPARATOR): Treatment in the control group:~For the study to be blind, the infusion of non-convalescent donor plasma, obtained before the start of the epidemic, is required to guarantee the absence of anti-COVID antibodies in the plasma of the control group.~Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment.

Based on this trial design, predict the completion outcome and termination type (if applicable).